Acceleron Pharma price target raised to $65 from $35 at Piper Jaffray Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Acceleron (XLRN) initiated with an Outperform at Oppenheimer... CSRA (CSRA) initiated with an Outperform at Cowen... HP Enterprise (HPE) initiated with a Neutral at Baird... Hortonworks (HDP) initiated with a Buy at Needham... IBM (IBM) initiated with an Outperform at JMP Securities... ITC Holdings (ITC) initiated with a Buy at Citi... Sucampo (SCMP) initiated with a Hold at Jefferies.
Piper Jaffray healthcare analyst holds an analyst/industry conference call Sr Research Analyst Schimmer, along with Dr. Alan Cohen, member of the Medical Advisory Board of the Cooley's Anemia Foundation, discuss the emerging treatment options for Beta Thalassemia and Sickle Cell and emerging clinical data for key programs including Bluebird and Bellicum Pharmaceuticals on an Analyst/Industry conference call to be held on November 20 at 1 pm.